Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MCLA-145 |
Trade Name | |
Synonyms | MCLA145|MCLA 145|anti-PD-L1/4-1BB bispecific antibody |
Drug Descriptions |
MCLA-145 is a bispecific antibody that binds to CD137 (4-1BB) and PD-L1 and simultaneously activates CD137 and inhibits PD-L1 signaling, which potentially relieves immune suppression resulting in reduced tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 539). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 TNFRSF9 Antibody 32 |
CAS Registry Number | NA |
NCIT ID | C160772 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
MCLA-145 | MCLA-145 | 0 | 1 |
MCLA-145 + Pembrolizumab | MCLA-145 Pembrolizumab | 0 | 0 |